SYMBIOTEC Q2 FY27: revenue up 43.0% to ₹280 Cr, net profit up 169.0% to ₹52 Cr
Results · Finvezto · 5 Nov 2026 · SYMBIOTEC (SYMBIOTEC)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 280 | - | +43.0% |
| Operating profit | 94 | - | +88.0% |
| Net profit | 52 | - | +169.0% |
| Operating margin | 33.6% | - | +8.0 pp |
| Net margin | 18.6% | - | +8.7 pp |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- Symbiotec Pharmalab Limited reported consolidated revenue of Rs 280 crore for Q2 FY27, up 43% year-on-year, with consolidated EBIDTA of Rs 94 crore (up 88%) and consolidated net profit of Rs 52 crore (up 169%). NSE filing
- Performance was supported by steady API business revenue of Rs 227 crore and milestone-based revenue of Rs 53 crore from complex injectables under a US licensing agreement. NSE filing
- Revenue was ₹280 Cr, up 43.0% on a year earlier. Finvezto data
Other figures
- Consol. Revenues: ₹280 Cr (+43.0% YoY)
- API Business Operating Revenue: ₹227 Cr (+16.0% YoY)
- API Business EBIDTA: ₹71 Cr (+21.0% YoY)
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.